NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

CTMX

CytomX Therapeutics Inc

Jul 11 • 04:00PM ET

2.42

Dollar change -0.18
Percentage change -6.92	%

Healthcare • Biotechnology • USA • NASD

Peers: FATE PRTA SRRK IMTX AFMD RCUS RNA ALXO XBIT PVLA

| Held by: VTI VXF FORH ITOT DFAC QQQS DFAS DXUV

Scroll to Statements

Index	-	P/E	4.88	EPS (ttm)	0.50	Insider Own	33.99%	Shs Outstand	157.54M	Perf Week	-3.20%
Market Cap	381.26M	Forward P/E	-	EPS next Y	-0.41	Insider Trans	-0.30%	Shs Float	103.99M	Perf Month	-10.37%
Enterprise Value	309.52M	PEG	-	EPS next Q	-0.06	Inst Own	35.39%	Short Float	21.53%	Perf Quarter	383.71%
Income	41.60M	P/S	2.58	EPS this Y	-124.50%	Inst Trans	33.95%	Short Ratio	4.29	Perf Half Y	137.25%
Sales	147.56M	P/B	7.79	EPS next Y	-337.98%	ROA	29.38%	Short Interest	22.39M	Perf YTD	134.95%
Book/sh	0.31	P/C	4.77	EPS next 5Y	-	ROE	-	52W High	3.10 -21.81%	Perf Year	79.26%
Cash/sh	0.51	P/FCF	-	EPS past 3/5Y	- -	ROIC	149.09%	52W Low	0.40 505.00%	Perf 3Y	22.84%
Dividend Est.	-	EV/EBITDA	8.22	Sales past 3/5Y	54.69% 19.16%	Gross Margin	98.86%	Volatility	8.29% 9.37%	Perf 5Y	-70.49%
Dividend TTM	-	EV/Sales	2.10	EPS Y/Y TTM	146.45%	Oper. Margin	24.37%	ATR (14)	0.22	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.73	Sales Y/Y TTM	23.81%	Profit Margin	28.19%	RSI (14)	52.70	Recom	1.50
Dividend Gr. 3/5Y	- -	Current Ratio	1.73	EPS Q/Q	61.71%	SMA20	0.90%	Beta	2.14	Target Price	5.50
Payout	0.00%	Debt/Eq	0.33	Sales Q/Q	22.80%	SMA50	12.69%	Rel Volume	0.29	Prev Close	2.60
Employees	121	LT Debt/Eq	0.11	Earnings	May 12 BMO	SMA200	99.99%	Avg Volume	5.21M	Price	2.42
IPO	Oct 08, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	116.35% 43.36%	Trades		Volume	1,522,138	Change	-6.92%

Date	Action	Analyst	Rating Change	Price Target Change
May-15-25	Upgrade	H.C. Wainwright	Neutral → Buy	$5
Apr-14-25	Resumed	Piper Sandler	Overweight	$3.25 → $2.50
May-28-24	Upgrade	Piper Sandler	Neutral → Overweight	$2.25 → $3.50
May-09-24	Upgrade	Wedbush	Neutral → Outperform	$8
May-06-24	Upgrade	Jefferies	Hold → Buy	$2.50 → $8
Apr-22-24	Upgrade	JP Morgan	Underweight → Neutral
Nov-14-22	Downgrade	BMO Capital Markets	Outperform → Market Perform	$3 → $2.60
Jul-07-22	Downgrade	Wedbush	Outperform → Neutral	$6 → $2
Jul-07-22	Downgrade	Piper Sandler	Overweight → Neutral	$10 → $1.50
Jul-07-22	Downgrade	Mizuho	Buy → Neutral	$16 → $4
Jul-07-22	Downgrade	Jefferies	Buy → Hold	$12 → $2
Jun-24-22	Initiated	BMO Capital Markets	Outperform	$9
Jan-18-22	Upgrade	Barclays	Underweight → Overweight	$7
Nov-15-21	Initiated	BTIG Research	Buy	$16
May-28-21	Downgrade	Barclays	Equal Weight → Underweight	$9 → $7
Mar-29-21	Initiated	JP Morgan	Overweight	$14
Mar-23-21	Upgrade	Jefferies	Hold → Buy
Sep-22-20	Downgrade	Guggenheim	Buy → Neutral
Jun-01-20	Downgrade	Jefferies	Buy → Hold	$16 → $10
May-14-20	Reiterated	H.C. Wainwright	Buy	$16 → $12

Show Previous Ratings

Jul-09-25 08:30AM	Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers (PR Newswire)
May-29-25 08:00AM	CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-19-25 08:00AM	CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA (pembrolizumab) in Patients with Metastatic Melanoma (GlobeNewswire)
May-13-25 01:58AM	Q1 2025 CytomX Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +17.37%
May-12-25 07:25AM	CytomX Therapeutics (CTMX) Beats Q1 Earnings and Revenue Estimates (Zacks) +129.43%
06:50AM	Loading…
06:50AM	CytomX Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock (GlobeNewswire)
06:22AM	CytomX Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
06:15AM	CytomX Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
06:15AM	CytomX Announces Positive Interim Data From Phase 1 Dose Escalation Study of EpCAM Antibody Drug Conjugate (CX-2051) Candidate in Patients with Advanced Colorectal Cancer (CRC) (GlobeNewswire)
May-09-25 05:40PM	SpringWorks Therapeutics (SWTX) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -14.83%
09:46AM	CytomX Therapeutics Inc (CTMX) Q1 2025 Earnings Report Preview: What to Look For (GuruFocus.com)
May-08-25 05:25PM	Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +13.48%
May-05-25 12:12PM	ANI Pharmaceuticals to Report Q1 Earnings: Is a Beat in the Cards? (Zacks) +19.85%
09:54AM	Perrigo to Report Q1 Earnings: Is a Beat in Store for the Stock? (Zacks)
08:00AM	CytomX Therapeutics to Report First Quarter 2025 Financial Results on May 12, 2025 (GlobeNewswire)
07:12AM	Loading…
07:12AM	Novavax to Report First-Quarter Earnings: Is a Beat in Store? (Zacks)
May-02-25 01:23PM	BioMarin's First-Quarter Earnings & Sales Beat Estimates (Zacks) +5.90%
Apr-30-25 05:50PM	Guardant Health (GH) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +14.23%
Apr-29-25 11:59AM	Corcept Therapeutics to Report Q1 Earnings: What's in the Cards? (Zacks) -7.95%
07:51AM	Vertex Gears Up to Report Q1 Earnings: Is a Beat in the Cards? (Zacks)
Apr-28-25 04:00PM	CytomX Therapeutics Presents Preclinical Data for mRNA Encoded Masked IL-12 Molecule in Collaboration with Moderna at AACR Annual Meeting (GlobeNewswire)
09:14AM	GSK to Report First-Quarter Earnings: Is a Beat in Store? (Zacks)
09:04AM	Zoetis Gears Up to Report Q1 Earnings: Here's What to Expect (Zacks)
Apr-25-25 11:59AM	CRISPR Therapeutics to Report Q1 Earnings: What's in the Cards? (Zacks) -7.29%
11:57AM	Can Moderna Keep the Beat Streak Alive This Earnings Season? (Zacks)
11:16AM	Recursion Pharmaceuticals to Report Q1 Earnings: What's in the Cards? (Zacks)
10:14AM	CytomX Gears Up to Report Q1 Earnings: Here's What to Expect (Zacks)
09:25AM	Beam Therapeutics to Report Q1 Earnings: What's in the Cards? (Zacks)
Apr-24-25 02:20PM	Merck Q1 Earnings & Sales Beat Estimates, '25 EPS Outlook Cut (Zacks)
06:31AM	Viking Therapeutics Q1 Loss Wider Than Expected, Sales Nil, Stock Dips (Zacks)
09:25AM	Loading…
Apr-23-25 09:25AM	Amicus Therapeutics to Report Q1 Earnings: What's in the Cards? (Zacks)
07:50AM	Incyte Gears Up to Report Q1 Earnings: Here's What You Should Know (Zacks)
Apr-22-25 10:39AM	Verastem Oncology to Report Q1 Earnings: What's in the Cards? (Zacks)
Apr-21-25 07:36AM	Viking Therapeutics to Report Q1 Earnings: What's in the Cards? (Zacks) +14.31%
Apr-16-25 07:32AM	SRPT Provides Pipeline Updates on Rare Muscular Disorder Therapies (Zacks)
Apr-10-25 07:00AM	VALN Doses First Infant With Shigella Vaccine in Mid-Stage Study (Zacks)
Apr-08-25 06:46AM	FDA Grants Three Fast Track Tags to Allogene's Autoimmune Disease Drug (Zacks) +5.47%
Apr-04-25 07:29AM	SRPT Stock Down After EMA Places Clinical Hold on DMD Gene Therapy (Zacks) -16.11%
Apr-03-25 10:14AM	BMRN's PKU Drug Palynziq Meets Goal in Late-Stage Pediatric Study (Zacks) -10.78%
Apr-01-25 10:50AM	CORT Shares Rise as Relacorilant Combo Meets Ovarian Cancer Study Goal (Zacks) -8.78%
Mar-28-25 11:20AM	FDA Accepts Merck's Filing for Subcutaneous Version of Keytruda (Zacks)
Mar-26-25 07:58AM	GSK Secures FDA Nod for Oral Antibiotic to Treat Urinary Tract Infection (Zacks)
02:06AM	FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib (Revised) (Zacks)
Mar-25-25 07:56AM	FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib (Zacks) -8.17%
Mar-21-25 01:03PM	Elevation Oncology Plunges 42% on Ending Development of Lead Drug (Zacks)
01:01PM	Akebia Stock Drops 28% on Pricing of $50M Common Stock Offering (Zacks)
Mar-19-25 01:38PM	SRPT Nosedives 27% on Patient Death Following DMD Therapy Infusion (Zacks) +10.93%
Mar-11-25 12:00PM	CytomX Therapeutics (CTMX) Upgraded to Strong Buy: Here's What You Should Know (Zacks) -7.36%
Mar-07-25 06:45PM	CytomX Therapeutics, Inc. (CTMX): Among the Cheap Growth Stocks to Buy Now (Insider Monkey) +7.71%
07:41AM	Q4 2024 CytomX Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
02:18AM	CytomX Therapeutics Inc (CTMX) Q4 2024 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
Mar-06-25 05:35PM	CytomX Therapeutics (CTMX) Tops Q4 Earnings and Revenue Estimates (Zacks)
04:10PM	CytomX Therapeutics Announces 2024 Financial Results and Provides Business Update (GlobeNewswire)
Mar-05-25 08:00AM	CytomX Therapeutics to Present at the Barclays 27th Annual Global Healthcare Conference (GlobeNewswire) -5.76%
07:35AM	Earnings To Watch: CytomX Therapeutics Inc (CTMX) Reports Q4 2024 Result (GuruFocus.com)
Feb-27-25 08:00AM	CytomX Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025 (GlobeNewswire)
Jan-08-25 08:00AM	CytomX Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-07-25 12:00PM	All You Need to Know About CytomX Therapeutics (CTMX) Rating Upgrade to Strong Buy (Zacks) -10.53%
Jan-06-25 04:05PM	CytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate Update (GlobeNewswire)
Dec-16-24 09:55AM	CytomX Therapeutics (CTMX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Nov-27-24 08:00AM	CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference (GlobeNewswire)
Nov-19-24 09:35AM	Down -25.59% in 4 Weeks, Here's Why CytomX Therapeutics (CTMX) Looks Ripe for a Turnaround (Zacks)
Nov-08-24 11:54AM	Q3 2024 CytomX Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +9.00%
02:32AM	CytomX Therapeutics Inc (CTMX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ... (GuruFocus.com)
Nov-07-24 05:55PM	CytomX Therapeutics (CTMX) Q3 Earnings and Revenues Top Estimates (Zacks)
04:49PM	CytomX Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:10PM	CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Nov-06-24 07:52AM	Earnings To Watch: CytomX Therapeutics Inc (CTMX) Reports Q3 2024 Result (GuruFocus.com)
Oct-31-24 08:00AM	CytomX Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024 (GlobeNewswire)
Sep-09-24 08:00AM	CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY , in a Phase 1 Study in Patients with Solid Tumors (GlobeNewswire)
Sep-04-24 08:00AM	CytomX Therapeutics to Present at Upcoming September Investor Conferences (GlobeNewswire) +11.61%
Aug-10-24 08:18AM	CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q2 2024 Earnings Call Transcript (Insider Monkey)
Aug-08-24 09:56PM	CTMX Stock Earnings: CytomX Therapeutics Beats EPS, Beats Revenue for Q2 2024 (InvestorPlace)
05:46PM	CytomX Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:10PM	CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Aug-01-24 08:00AM	CytomX Therapeutics to Report Second Quarter 2024 Financial Results on August 8, 2024 (GlobeNewswire)
Jul-25-24 02:26AM	CytomX Therapeutics, Inc. (CTMX): The Best One-Dollar Stock to Buy Now? (Insider Monkey)
Jun-18-24 08:00AM	CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference (GlobeNewswire) -5.84%
Jun-17-24 04:15PM	CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer (GlobeNewswire)
Jun-05-24 06:00AM	Buy Alert: 3 Penny Stocks That Will Explode in 2024 (InvestorPlace)
Jun-03-24 09:17AM	Biotech Advances in 2024: Innovative Treatments Aim to Boost Pancreatic Cancer Survival Rates (PR Newswire)
May-29-24 06:25AM	No Memes, Ma'am! Try a Sensible Biotech Bet With CytomX Therapeutics Stock. (InvestorPlace)
May-22-24 04:05PM	CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-16-24 04:15PM	CytomX Therapeutics Announces New Employment Inducement Grants (GlobeNewswire) -5.50%
May-15-24 11:14AM	Biotech Companies Making Strides in Pancreatic Cancer Treatment and Early Detection (PR Newswire)
May-09-24 04:17PM	CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q1 2024 Earnings Call Transcript (Insider Monkey) -51.31%
11:56AM	Why Is CytomX (CTMX) Stock Down 43% Today? (InvestorPlace)
11:32AM	BMO Capital Adjusts Price Target on CytomX Therapeutics to $3.59 From $3.25, Maintains Market Perform Rating (MT Newswires)
08:12AM	Q1 2024 CytomX Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
07:48AM	Wedbush Upgrades CytomX Therapeutics to Outperform From Neutral, Adjusts Price Target to $8 From $3 (MT Newswires)
07:29AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace)
04:01AM	CytomX Therapeutics Inc (CTMX) Q1 2024 Earnings Call Transcript Highlights: Strategic ... (GuruFocus.com)
May-08-24 09:58PM	CTMX Stock Earnings: CytomX Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
04:30PM	CytomX Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
04:10PM	CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
04:10PM	CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY T-Cell Engager) (GlobeNewswire)
May-07-24 04:15PM	CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA (pembrolizumab) (GlobeNewswire) -6.86%
May-06-24 07:09AM	Jefferies Upgrades CytomX Therapeutics to Buy, Price Target at $8 (MT Newswires)
May-02-24 08:08AM	CytomX Therapeutics (CTMX) Surges 214.7%: Is This an Indication of Further Gains? (Zacks) -12.28%
07:37AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace)

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Ogden Christopher	Chief Financial Officer	Jun 13 '25	Option Exercise	0.00	37,500	0	236,885	Jun 17 04:11 PM
Ogden Christopher	Chief Financial Officer	Jun 16 '25	Sale	2.69	10,614	28,540	226,271	Jun 17 04:11 PM
Ogden Christopher	Chief Financial Officer	Jun 13 '25	Sale	2.95	1,641	4,841	199,385	Jun 17 04:11 PM
BELVIN MARCIA	SVP, Chief Scientific Officer	Jun 13 '25	Option Exercise	0.00	37,500	0	286,136	Jun 17 04:10 PM
BELVIN MARCIA	SVP, Chief Scientific Officer	Jun 16 '25	Sale	2.69	13,884	37,334	272,252	Jun 17 04:10 PM
McCarthy Sean A.	CEO	Jun 13 '25	Option Exercise	0.00	150,000	0	1,145,195	Jun 17 04:09 PM
McCarthy Sean A.	CEO	Jun 16 '25	Sale	2.69	55,511	149,264	1,089,684	Jun 17 04:09 PM
McCarthy Sean A.	CEO	Mar 18 '25	Sale	0.60	37,656	22,556	995,195	Mar 20 04:34 PM
Ogden Christopher	Chief Financial Officer	Mar 18 '25	Sale	0.60	8,551	5,122	201,026	Mar 20 04:33 PM
Chu Yu-Waye	Chief Medical Officer	Mar 18 '25	Sale	0.60	4,025	2,411	135,725	Mar 20 04:32 PM
ROWLAND LLOYD A	General Counsel	Mar 18 '25	Sale	0.60	10,203	6,112	120,594	Mar 20 04:32 PM
BELVIN MARCIA	SVP, Chief Scientific Officer	Mar 18 '25	Sale	0.60	19,512	11,688	248,636	Mar 20 04:31 PM
Landau Jeffrey B	Chief Business Officer	Aug 20 '24	Option Exercise	0.00	11,250	0	123,237	Aug 22 06:01 PM
Landau Jeffrey B	Chief Business Officer	Aug 20 '24	Sale	1.23	4,181	5,139	119,056	Aug 22 06:01 PM
BELVIN MARCIA	SVP, Chief Scientific Officer	Aug 20 '24	Option Exercise	0.00	11,250	0	179,829	Aug 22 06:01 PM
BELVIN MARCIA	SVP, Chief Scientific Officer	Aug 20 '24	Sale	1.23	4,181	5,139	175,648	Aug 22 06:01 PM
ROWLAND LLOYD A	General Counsel	Aug 20 '24	Option Exercise	0.00	11,250	0	134,978	Aug 22 06:00 PM
ROWLAND LLOYD A	General Counsel	Aug 20 '24	Sale	1.23	4,181	5,139	130,797	Aug 22 06:00 PM
Ogden Christopher	Chief Financial Officer	Aug 20 '24	Option Exercise	0.00	6,875	0	110,061	Aug 22 05:59 PM
Ogden Christopher	Chief Financial Officer	Aug 20 '24	Sale	1.23	1,984	2,439	108,077	Aug 22 05:59 PM
McCarthy Sean A.	CEO	Aug 20 '24	Option Exercise	0.00	37,500	0	671,749	Aug 22 05:58 PM
McCarthy Sean A.	CEO	Aug 20 '24	Sale	1.23	13,898	17,082	657,851	Aug 22 05:58 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CTMX

CytomX Therapeutics Inc

Upgrade your FINVIZ experience